Formed in 2022, The British Society for Haematology (BSH) Laboratory Special Interest Group (SIG) incorporates both benign and malignant laboratory haematology. The SIG is comprised of BSH members and non-members who are a mix of medics and scientists.
The group will focus on general laboratory haematology, haematological malignancy diagnostics and the investigation of constitutional haematological disorders in the UK. These will continue to be a growth area over the next few decades, particularly with the advent of genomic and personalised medicine. Within the SIG, we will have separate sub-speciality workstreams to allow professionals to coalesce around areas of their particular interest, such as HMDS or red cell haematology.
These workstreams will operate and report through the SIG organising committee.
Officers of the Laboratory SIG
Dr Tom Butler (Chair)
Consultant Haematologist and Haematopathologist, Barts Health NHS Trust
Clinical Director, NHS East and South East London Pathology Partnership
Dr Andrew McGregor
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Andrew Wilson
University College London NHS Foundation Trust
Dr Anna Godfrey
Consultant Haematologist and Clinical Lead
Haematopathology and Oncology Diagnostics Service, Cambridge University Hospitals NHS Foundation Trust
Ms April Sellors
Consultant Clinical Scientist
HMDL Laboratory, University Hospitals of Leicester NHS Trust
Dr Emma Das-Gupta
Nottingham University Hospitals NHS Trust
Professor John Snowden
Consultant Haematologist, Sheffield Teaching Hospitals NHS Foundation Trust
Honorary Professor, University of Sheffield
Honorary Clinical Professor, University College London
Dr Linda Barton
Consultant Haematologist, University Hospitals of Leicester NHS Trust
Honorary Associate Professor, University of Leicester
Dr Nagumantry Kumar
Dr Noemi Roy
Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust
Associate Professor of Molecular Haematology, University of Oxford
Dr Rachel Brown
Haematology Consultant and Clinical Director for Laboratory Haematology
Manchester University NHS Foundation Trust
Mr Robert Baker
Molecular Haematology Operations Manager
Health Service Laboratories
Dr Shireen Kassam
Consultant Haematologist and Lifestyle Medicine Physician, London South-East
KSS Training Programme Director, King’s College Hospital, London
Dr Timothy Farren
Head of Immunophenotyping and Scientific Lead for SIHMDS
NHS East and South East London Pathology Partnership
Join the Laboratory Special Interest Group.
The SIG welcomes both members and non-members of the BSH who have a special interest in Laboratory Haematology and is free to join.
The Fellowship in Clinical AI is a year-long programme which is integrated part-time alongside training or employment.
Our fellows are smart and energetic individuals who will lead the charge to revolutionise clinical workflows with AI in the NHS.
Fellows are recruited competitively from various clinical workforce groups including doctors, dentists, nurses & midwives, AHPs, and pharmacy professionals.
Fellows will spend twelve months (August 2024- August 2025) working two days per week on an immersive AI deployment project within a multidisciplinary team. They will be supervised by a senior clinician in an NHS trust with expertise in clinical AI.
Project work is complemented by regular small group workshops and a programme of e-learning, so the fellow is exposed to all parts of the AI lifecycle.
BSH will fund two fellows working on AI projects specifically aligned with clinical haematology.
Through a shared application process, BSH applicants who are not successful in securing a BSH-funded place will still have the opportunity to apply to other projects offered on the fellowship.
For more information on this exciting opportunity, visit the Fellowship website. Please note that there is a dedicated BSH FAQ section on the Cohort 3 application page.
An applicant webinar will be held on the 22nd of November 2023. Please follow the link to sign up for this.
We are also keen to hear from any members with relevant expertise who may be interested in supervising a Clinical AI Fellow. Please contact the Programme Lead, Dr Alexander Deng ([email protected]), to express your interest or for any related enquiries.
Thank you to those who completed our HMDS survey last year. A summary of the results is available.
The results have already been presented at a BSH-supported HMDS network meeting in February 2023, as well as at the Lab SIG session of our BSH Annual Scientific Meeting (ASM) in April 2023.
The ASM presentation discusses the results of the survey, as well as outlining national issues and progress on forming a UK HMDS network.
Below you will find further information on the UK GLHs, their MDTs and the tests they provide.
The MDT is held from 14:00 to 15:00 every Thursday.
Melanie Proven, Ria Burns
Oxford Molecular Haematology Laboratory
Rare disease molecular haematology request form
The MDT is held every two weeks on a Friday from 14:00 to 15:00 via Teams.
Organiser: Dr Dalia Khan, Consultant Haematologist, Oxford
MDT coordinator: Gabi Niemiec
Prof Andrew Mumford
Dr Sarah Westbury
Dr Nicola Curry
Dr Sarah Mangles
Dr Rashid Kazmi
Dr Claire Lentaigne
Dr Gillian Lowe
Dr Carl Fratter
Dr Patricia Bignell
Dr Dalia Khan
Genetics MDT proforma
The MDT is held on the third Friday of each month.
The four GLH scientists
Genomics diagnostic laboratory generic request form
The MDT is held on the fourth Thursday of every second month, either at 11:00 or 14:00.
NW GLH and East GLH Genetics Specialist teams (including invited guests).
Laura and Rachel, MDT Coordinators at Manchester University NHS Foundation Trust.
Genomics diagnostic laboratory generic request form
The MDT is held on the first Monday of each month from 10:00-11:30.
Chair: Dr Elizabeth Horn
Dr Elizabeth Horn
For some time, we have been anticipating the publication of two new haematological malignancy diagnostic classifications: the World Health Organisation (WHO) 5th edition and the International Consensus Classification (ICC), the outlines of which have recently been published in Leukemia and Blood, respectively.
While, for the most part, they agree and overlap with each other, the two classifications do differ in some areas.
The British Society for Haematology (BSH) and the British Lymphoma Pathology Group (BLPG) have been asked to help. We want to provide some interim guidance for members whilst planning formal, definitive guidance.